FCGR3A and rheumatoid arthritis: The expression of CD16 on CD14++ monocytes prior to initiation of therapy in early-RA patients was found to be predictive of response to methotrexate; mean CD16 expression on CD14++ monocytes was significantly higher in non-responders compared to moderate and good responders (p = 0.0009, Table 1).